| 000 | 01397 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250518085812.0 | ||
| 264 | 0 | _c20210107 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1744-7607 | ||
| 024 | 7 |
_a10.1080/17425255.2020.1735351 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDutta, Deep | |
| 245 | 0 | 0 |
_aInjectable combination therapies for the management of diabetes: an Indian perspective. _h[electronic resource] |
| 260 |
_bExpert opinion on drug metabolism & toxicology _cMar 2020 |
||
| 300 |
_a209-216 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 | _aCosts and Cost Analysis |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aDisease Management |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide-1 Receptor _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aIndia _xepidemiology |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInsulin _xadministration & dosage |
| 650 | 0 | 4 | _aGlucagon-Like Peptide-1 Receptor Agonists |
| 700 | 1 | _aKhandelwal, Deepak | |
| 700 | 1 | _aKalra, Sanjay | |
| 773 | 0 |
_tExpert opinion on drug metabolism & toxicology _gvol. 16 _gno. 3 _gp. 209-216 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/17425255.2020.1735351 _zAvailable from publisher's website |
| 999 |
_c30673237 _d30673237 |
||